Jyong Biotech (MENS) Registration Filing summary

Company overview and business model

• Science-driven biotech firm based in Taiwan, focused on developing and commercializing innovative plant-derived drugs for urinary system diseases, targeting the U.S., EU, and Asia markets.

• Core pipeline includes MCS-2 for benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS), PCP for prostate cancer prevention, and IC for interstitial cystitis.

• Operations are conducted through five wholly owned subsidiaries in Taiwan, Singapore, Hong Kong, and China; holding company structure based in the Cayman Islands.

• No commercialized products to date; business model relies on R&D, clinical trials, and future out-licensing or commercialization of drug candidates.

Financial performance and metrics

• No revenue generated as of June 30, 2024; accumulated deficit of $31.4 million and net working capital deficit of $11.7 million.

• Net losses of $6.6 million (2022), $4.4 million (2023), and $1.3 million (six months ended June 30, 2024).

• Research and development expenses were $1.3 million (2022), $1.1 million (2023), and $0.5 million (six months ended June 30, 2024).

• Significant liabilities include $7.5 million in short- and long-term bank loans due within 12 months, and $19.0 million in guarantee liabilities related to litigation.

• Auditors have raised substantial doubt about the company’s ability to continue as a going concern.

Use of proceeds and capital allocation

• Proceeds from the IPO will primarily fund Phase III trials of MCS-2 (API-2), earlier phase trials if comparability is not demonstrated, Phase II trial of PCP, Phase I trial of IC, and general corporate purposes.

• Approximately 40% allocated to MCS-2 Phase III trials, 25% to earlier phase trials, 10% to PCP Phase II, 5% to IC Phase I, and 20% for general purposes.

• A portion of proceeds will address debt obligations due to litigation and commitments with Taizhou Resources Bureau.

• Additional capital of approximately $10 million will be needed to complete development and commercialization of drug candidates.